| Systematic (IUPAC) name | |
|---|---|
| (3R,5R)-5-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 617720-02-2 |
| ATC code | ? |
| PubChem | CID 9865375 |
| ChemSpider | 8041067 |
| Synonyms | HT-0712, IPL 455,903 |
| Chemical data | |
| Formula | C25H31NO3 |
| Mol. mass | 393.53 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
HT-0712 is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in San Diego, California. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.
Contents |
HT-0712 appears to act as a PDE4 inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.
The side effects of the drug are not yet fully known.
Middle-aged people, seniors, and possibly those suffering from dementia, who have a hard time remembering everyday events, can possibly benefit from this drug.
Many students may be inclined to use nootropics for school and college life for exams and finals. This could also be an effective alternative or adjunctive to the use of caffeine as a study aid.
|
||||||||||||||||||||||||||||||||